NZ512005A - New cancer treatments - Google Patents

New cancer treatments

Info

Publication number
NZ512005A
NZ512005A NZ512005A NZ51200599A NZ512005A NZ 512005 A NZ512005 A NZ 512005A NZ 512005 A NZ512005 A NZ 512005A NZ 51200599 A NZ51200599 A NZ 51200599A NZ 512005 A NZ512005 A NZ 512005A
Authority
NZ
New Zealand
Prior art keywords
cell lines
prostate cancer
heterogeneity
disclosed
cancer treatments
Prior art date
Application number
NZ512005A
Other languages
English (en)
Inventor
Angus George Dalgleish
Peter Michael Smith
Andrew Derek Sutton
Anthony Ian Walker
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Priority to NZ527763A priority Critical patent/NZ527763A/en
Publication of NZ512005A publication Critical patent/NZ512005A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NZ512005A 1998-12-10 1999-12-09 New cancer treatments NZ512005A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ527763A NZ527763A (en) 1998-12-10 1999-12-09 Allogeneic immunotherapeutic agent comprising three human prostate tumour cell lines derived from three different primary tumours useful in treating prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments

Publications (1)

Publication Number Publication Date
NZ512005A true NZ512005A (en) 2004-01-30

Family

ID=10843925

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512005A NZ512005A (en) 1998-12-10 1999-12-09 New cancer treatments

Country Status (19)

Country Link
US (1) US6699483B1 (https=)
EP (1) EP1137434B1 (https=)
JP (1) JP4607330B2 (https=)
KR (1) KR100612552B1 (https=)
AT (1) ATE412425T1 (https=)
AU (1) AU777969B2 (https=)
CA (1) CA2354046C (https=)
CZ (1) CZ20012033A3 (https=)
DE (1) DE69939837D1 (https=)
ES (1) ES2315024T3 (https=)
GB (1) GB9827103D0 (https=)
HU (1) HUP0104857A3 (https=)
IL (2) IL143295A0 (https=)
MX (1) MXPA01005815A (https=)
NO (1) NO326035B1 (https=)
NZ (1) NZ512005A (https=)
PL (1) PL348829A1 (https=)
WO (1) WO2000033870A2 (https=)
ZA (1) ZA200104163B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1272617T3 (da) * 2000-04-01 2011-08-22 Onyvax Ltd Prostata cellelinier og deres anvendelse
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
AU2004270113A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
EP4006145A4 (en) * 2019-07-24 2023-08-23 Slbigen Inc. Method for preparation of immortalized stem cell line and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
WO1997024132A1 (en) 1995-12-28 1997-07-10 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
WO1997028255A1 (en) * 1996-02-02 1997-08-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
CA2349217C (en) * 1998-11-03 2012-07-31 Johns Hopkins University Cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
GB9827103D0 (en) 1999-02-03
AU777969B2 (en) 2004-11-04
NO20012818L (no) 2001-06-07
WO2000033870A2 (en) 2000-06-15
JP2002531521A (ja) 2002-09-24
CA2354046C (en) 2011-02-15
KR20010090873A (ko) 2001-10-19
HUP0104857A3 (en) 2004-04-28
WO2000033870A3 (en) 2000-08-17
AU1668700A (en) 2000-06-26
NO326035B1 (no) 2008-09-01
EP1137434B1 (en) 2008-10-29
ZA200104163B (en) 2002-02-04
ES2315024T3 (es) 2009-03-16
PL348829A1 (en) 2002-06-17
EP1137434A2 (en) 2001-10-04
IL143295A0 (en) 2002-04-21
JP4607330B2 (ja) 2011-01-05
US6699483B1 (en) 2004-03-02
IL143295A (en) 2006-04-10
CZ20012033A3 (cs) 2001-10-17
NO20012818D0 (no) 2001-06-07
CA2354046A1 (en) 2000-06-15
KR100612552B1 (ko) 2006-08-11
HUP0104857A2 (hu) 2002-04-29
MXPA01005815A (es) 2003-04-02
DE69939837D1 (de) 2008-12-11
ATE412425T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
NZ512005A (en) New cancer treatments
JP2006525995A5 (https=)
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
ATE404226T1 (de) Zusammensetzung enthaltend auf festen teilchen immobilisierte radioisotopen, sowie deren verwendung in der brachytherapie
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
Naylor et al. Treatment of advanced melanoma with laser immunotherapy and ipilimumab
Nikolsky Break in the cosmic ray spectrum or confinement violation near 10 6 TeV?
WO2000033869A3 (en) Use of human prostrate cell lines in cancer treatment
EP1223952A4 (en) METHODS FOR TREATING SOLID TUMORS AND METASTASES WITH GENE THERAPY
IL114382A0 (en) Cancer therapy using lymphotoxin
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
GB2419530A (en) Human prostate cell lines in cancer treatment
WO2006096206A3 (en) Method for preparing particles of radioactive powder containing cesium-131 for use in brachytherapy sources
Talbot et al. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors
EP1351967A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
Antonadou et al. Comparative study between exclusive irradiation or combined with IFN-[alpha]-2a and isotretinoin in stage IIB and III cervical carcinoma
Matsuura et al. Treatment results of stage I or II oral tongue cancer with interstitial brachytherapy-maximum tumor thickness is a good prognostic indicator
Armstrong et al. The role of brachytherapy in carcinoma of the extrahepatic biliary system
MX2025009771A (es) Conjugados anticuerpo-farmaco, composiciones farmaceuticas y usos de los mismos
Park et al. POD-03.01: Development and application of mixed vaccines in renal cell carcinoma: combining autologous tumor cells with dendritic cells derived from autologous or allogeneic origin
WO2000071157A3 (en) New vaccine formulations - 1

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)